Latest Janssen Biotech Inc. Stories
SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
LONDON, SUNNYVALE, Calif. and RARITAN, N.J., Nov.
"Get Your Full Course" addresses diet and nutritional considerations related to inflammatory bowel diseases and highlights Sunny's personal story of living with ulcerative colitis HORSHAM,
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S.
- a meat pie that is usually eaten at Christmas in Quebec